GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on ...

The Food and Drug Administration approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients with the ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, manufactured by Novo Nordisk. Reuters Eli Lilly said Wednesday that its obesity drug Zepbound ...

Eli Lillys Zepbound set to eclipse Wegovy in U.S. obesity drug market Eli Lillys new obesity drug poised to challenge ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...

Eli Lilly and Company has invested more than $20 billion in its manufacturing capabilities since 2020 to help meet high ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...